Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Is there a reproducibility crisis in the biomedical sciences? If so, what can early-career researchers do about it? This was the theme of the second edition of the Oxford-Berlin Summer School on Open Research.

For five days in September sixty PhD students and postdoctoral researchers from Oxford, Berlin and other universities came together at Green Templeton College and the Weston Library to attend lectures and interactive workshops on how to incorporate open and reproducible research practices in their own projects.

The summer school was co-organised by Reproducible Research Oxford (RROx) and the QUEST Center at the Berlin Institute of Health with generous support from the Oxford-Berlin Research Partnership and the Bodleian Libraries.

A diverse programme of lectures and workshops focused on various aspects of open and reproducible research across the cycle of a research project. Participants selected from a range of workshops, covering topics such as the importance of systematic literature reviews when developing hypotheses, avoiding biases and confounding in study design, introductory courses in Python and R to produce reproducible workflows for data analysis, and publishing research outputs such as data and materials. Many participants said afterwards that it was extremely difficult to only choose one workshop per day because they were all so interesting and relevant. 

Highlights of the week were the keynote lecture on 'Data liberation' given by Professor Denise Lievesley (Principal of Green Templeton College) and informal discussions among early-career researchers on advantages of, and barriers to, working more openly within the current incentive structures.

The event was very successful and brought together lecturers and tutors from Berlin and across Oxford, including Medical Sciences, (Experimental Psychology, NDPH, Biomedical Services, NDORMS, NDS, PHC and Psychiatry), Social Sciences, MPLS, IT Services and the Bodleian Libraries.

Reproducible Research Oxford will continue to harness the expertise and energy of everyone involved in the summer school and plan to deliver more training to Oxford-based early-career researchers in the future.

If you would like to hear more about their work, visit their website or follow them on Twitter.

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.